CELGENE IN TALKS TO BUY BIOTECH COMPANY JUNO

Shares of Juno Therapeutics soared

47% after it was reported biotech drugmaker Celgene might buy it. Juno is one of several companies developing therapies that involve genetically engineering patients’ blood cells to fight cancer. The news comes less than a week after the biotech giant said it would buy Impact Biomedicines for

$7 billion.